Altamira Therapeutics Earnings Call: Growth Amid Challenges

Altamira Therapeutics Ltd. ((CYTOF)) has held its Q4 earnings call. Read on for the main highlights of the call.

Altamira Therapeutics Ltd. recently held its earnings call, revealing a mixed sentiment. The company showcased significant progress in its RNA delivery business through new partnerships and patent filings, despite challenges such as Nasdaq delisting and an increased net loss. Altamira’s strategic moves, including engaging private equity investors and planning a spin-off for its RNA delivery activities, indicate a proactive approach towards future growth.

RNA Delivery Business Momentum

Altamira has made notable strides in its RNA delivery business by securing two new partners for its xPhore platform. This development underscores the platform’s versatility, particularly with circular RNA, and opens up new business opportunities for the company.

New Collaborations

The company expanded its horizons by entering into a new collaboration agreement with a firm in the radiopharmaceutical sector. This partnership is expected to enhance Altamira’s capabilities in cancer treatment, marking a significant step forward.

Bentrio Nasal Spray Market Expansion

Altamira is on the verge of expanding its market reach for Bentrio nasal spray, with marketing approval anticipated in Mainland China. Additionally, the company secured a U.S. patent for Bentrio’s composition, ensuring protection until 2040.

Decreased Cash Used in Operations

The company reported a significant reduction in cash used in operations, decreasing from $12.8 million in 2023 to $6.1 million in 2024. This decrease reflects Altamira’s efforts to streamline its operations and manage resources efficiently.

Patent Application for CycloPhore

Altamira filed a provisional patent application for CycloPhore with the U.S. Patent Office. This move highlights the potential of CycloPhore in the circular RNA space, further strengthening Altamira’s position in the market.

Nasdaq Delisting

Altamira faced a setback with the delisting of its common shares from Nasdaq due to a minimum bid price issue. This development has impacted the company’s ability to secure funding from public markets.

Increased Net Loss

The company reported an increased net loss of $8.5 million for 2024, compared to $4.3 million in the previous year. It’s important to note that 2023 included a profit from discontinued operations, which affected the comparison.

Decreased Shareholders’ Equity

Shareholders’ equity saw a decline from $7.7 million at the end of 2023 to $6.6 million by the end of 2024, reflecting the financial challenges faced by Altamira.

Forward-Looking Guidance

Altamira provided forward-looking guidance, indicating a slight increase in operating loss from continuing operations, rising from $6.6 million in 2023 to $6.9 million in 2024. Research and development expenses increased, while general and administrative expenses decreased. The company anticipates a reduction in operating expenses following the partial spin-off of its RNA delivery subsidiary, ATAG. Altamira plans to fund future operations through existing cash, private equity, and strategic partnerships.

In conclusion, Altamira Therapeutics Ltd.’s earnings call painted a picture of a company navigating through challenges while making strategic moves for future growth. Despite the increased net loss and Nasdaq delisting, the company is making significant progress in its RNA delivery business and expanding its market reach. Altamira’s proactive strategies and forward-looking guidance suggest a commitment to overcoming current hurdles and achieving long-term success.